Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
Subscribe To Our Newsletter & Stay Updated
